These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
133 related articles for article (PubMed ID: 19014930)
1. Brivaracetam and seletracetam, two new SV2A ligands, improve paroxysmal dystonia in the dt sz mutant hamster. Hamann M; Sander SE; Richter A Eur J Pharmacol; 2008 Dec; 601(1-3):99-102. PubMed ID: 19014930 [TBL] [Abstract][Full Text] [Related]
2. Piracetam and levetiracetam, two pyrrolidone derivatives, exert antidystonic activity in a hamster model of paroxysmal dystonia. Löscher W; Richter A Eur J Pharmacol; 2000 Mar; 391(3):251-4. PubMed ID: 10729365 [TBL] [Abstract][Full Text] [Related]
3. Binding characteristics of brivaracetam, a selective, high affinity SV2A ligand in rat, mouse and human brain: relationship to anti-convulsant properties. Gillard M; Fuks B; Leclercq K; Matagne A Eur J Pharmacol; 2011 Aug; 664(1-3):36-44. PubMed ID: 21575627 [TBL] [Abstract][Full Text] [Related]
4. Role of striatal NMDA receptor subunits in a model of paroxysmal dystonia. Avchalumov Y; Sander SE; Richter F; Porath K; Hamann M; Bode C; Kirschstein T; Köhling R; Richter A Exp Neurol; 2014 Nov; 261():677-84. PubMed ID: 25139804 [TBL] [Abstract][Full Text] [Related]
5. Anti-convulsive and anti-epileptic properties of brivaracetam (ucb 34714), a high-affinity ligand for the synaptic vesicle protein, SV2A. Matagne A; Margineanu DG; Kenda B; Michel P; Klitgaard H Br J Pharmacol; 2008 Aug; 154(8):1662-71. PubMed ID: 18500360 [TBL] [Abstract][Full Text] [Related]
6. Interaction of Approved Drugs with Synaptic Vesicle Protein 2A. Danish A; Namasivayam V; Schiedel AC; Müller CE Arch Pharm (Weinheim); 2017 Apr; 350(3-4):. PubMed ID: 28220535 [TBL] [Abstract][Full Text] [Related]
7. The carbonic anhydrase inhibitor acetazolamide exerts antidystonic effects in the dt(sz) mutant hamster. Richter A; Hamann M Eur J Pharmacol; 2004 Oct; 502(1-2):105-8. PubMed ID: 15464095 [TBL] [Abstract][Full Text] [Related]
8. Antidystonic efficacy of nitric oxide synthase inhibitors in a rodent model of primary paroxysmal dystonia. Richter A; Löschmann PA; Löscher W Br J Pharmacol; 2000 Nov; 131(5):921-6. PubMed ID: 11053212 [TBL] [Abstract][Full Text] [Related]
9. Evidence for a differential interaction of brivaracetam and levetiracetam with the synaptic vesicle 2A protein. Wood MD; Gillard M Epilepsia; 2017 Feb; 58(2):255-262. PubMed ID: 28012162 [TBL] [Abstract][Full Text] [Related]
10. Effects of the kynurenine 3-hydroxylase inhibitor Ro 61-8048 after intrastriatal injections on the severity of dystonia in the dt sz mutant. Hamann M; Sander SE; Richter A Eur J Pharmacol; 2008 May; 586(1-3):156-9. PubMed ID: 18353306 [TBL] [Abstract][Full Text] [Related]
11. Effects of locally administered pentylenetetrazole on nigral single unit activity and severity of dystonia in a genetic model of paroxysmal dystonia. Fedrowitz M; Hamann M; Rehders JH; Richter A; Gernert M J Neurosci Res; 2002 Jun; 68(5):595-603. PubMed ID: 12111849 [TBL] [Abstract][Full Text] [Related]
12. Effects of intrastriatal injections of glutamate receptor antagonists on the severity of paroxysmal dystonia in the dtsz mutant. Sander SE; Richter A Eur J Pharmacol; 2007 Jun; 563(1-3):102-8. PubMed ID: 17349621 [TBL] [Abstract][Full Text] [Related]
13. Polyamines in a genetic animal model of paroxysmal dyskinesia. Richter A; Morrison LD Brain Res; 2003 Aug; 981(1-2):168-73. PubMed ID: 12885438 [TBL] [Abstract][Full Text] [Related]
14. Brivaracetam: Rationale for discovery and preclinical profile of a selective SV2A ligand for epilepsy treatment. Klitgaard H; Matagne A; Nicolas JM; Gillard M; Lamberty Y; De Ryck M; Kaminski RM; Leclercq K; Niespodziany I; Wolff C; Wood M; Hannestad J; Kervyn S; Kenda B Epilepsia; 2016 Apr; 57(4):538-48. PubMed ID: 26920914 [TBL] [Abstract][Full Text] [Related]
15. Alterations of M1 and M4 acetylcholine receptors in the genetically dystonic (dt Hamann M; Plank J; Richter F; Bode C; Smiljanic S; Creed M; Nobrega JN; Richter A Neuroscience; 2017 Aug; 357():84-98. PubMed ID: 28596119 [TBL] [Abstract][Full Text] [Related]
16. Profile of the new pyrrolidone derivative seletracetam (ucb 44212) in animal models of epilepsy. Matagne A; Margineanu DG; Potschka H; Löscher W; Michel P; Kenda B; Klitgaard H Eur J Pharmacol; 2009 Jul; 614(1-3):30-7. PubMed ID: 19383493 [TBL] [Abstract][Full Text] [Related]
17. Autoradiographic and pharmacological studies on the role of dopamine D3 receptors in genetically dystonic (dt(sz)) hamsters. Sander SE; Raymond R; Nobrega JN; Richter A Pharmacol Biochem Behav; 2010 Aug; 96(2):136-40. PubMed ID: 20451545 [TBL] [Abstract][Full Text] [Related]
18. Gabapentin decreases the severity of dystonia at low doses in a genetic animal model of paroxysmal dystonic choreoathetosis. Richter A; Löscher W Eur J Pharmacol; 1999 Mar; 369(3):335-8. PubMed ID: 10225372 [TBL] [Abstract][Full Text] [Related]
19. Persistent changes of corticostriatal plasticity in dt(sz) mutant hamsters after age-dependent remission of dystonia. Avchalumov Y; Volkmann CE; Rückborn K; Hamann M; Kirschstein T; Richter A; Köhling R Neuroscience; 2013 Oct; 250():60-9. PubMed ID: 23827309 [TBL] [Abstract][Full Text] [Related]
20. Further evidence for a differential interaction of brivaracetam and levetiracetam with the synaptic vesicle 2A protein. Wood MD; Sands ZA; Vandenplas C; Gillard M Epilepsia; 2018 Sep; 59(9):e147-e151. PubMed ID: 30144048 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]